Tuesday, AstraZeneca Plc (NASDAQ:AZN) announced topline data from the CAPItello-290 Phase 3 trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC). The study did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of patients with tumors harboring specific biomarker alterations (PIK3CA, AKT1, or PTEN). Also Read: AstraZeneca Says Calquence/Chemo Combo ...